The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 5,175 | - | - | 58,839 |
| Salaries | 68,599 | - | - | 242,795 |
| Consumables | 8,927 | - | - | 77,543 |
| Platform | 14,377 | - | - | 15,876 |
| Discovery | 37,049 | - | - | 30,480 |
| Clinical development | 10,814 | - | - | 43,713 |
| Depreciation and amortization | 18,707 | - | - | 36,494 |
| Other segment items | 18,905 | - | - | 90,942 |
| Loss from operations | -172,203 | - | - | -479,004 |
| Other non-operating income (loss), net | 9,952 | - | - | 14,216 |
| Income tax benefit (expense) | 2 | - | - | -1,127 |
| Net loss | -162,253 | -171,897 | -202,487 | -178,906 |
| Depreciation and amortization | 21,043 | 23,849 | 19,331 | 12,951 |
| Stock-based compensation | 25,243 | 26,159 | 36,058 | 30,784 |
| Asset impairment | 0 | 0 | 5,956 | 0 |
| Lease expense | 5,264 | 5,625 | 6,130 | 5,461 |
| Loss on disposal of a business | 0 | 0 | -4,502 | - |
| Acquired ipr&d | 22,082 | - | - | - |
| Other, net | 2,443 | -4,693 | -4,405 | -8,232 |
| Other receivables and assets | -3,529 | -25,407 | -4,839 | 4,828 |
| Prepaid data assets | - | -29,601 | -27,131 | - |
| Accrued data liability | 0 | 20,258 | - | - |
| Unearned revenue | -6,631 | -13,621 | -9,762 | -5,664 |
| Accounts payable | -5,890 | -4,837 | 3,692 | 8,122 |
| Accrued development expense | -4,055 | -754 | 599 | 2,359 |
| Accrued expenses and other current liabilities | -8,033 | 11,378 | -26,591 | 10,520 |
| Lease liabilities | -5,216 | -5,148 | -5,760 | -4,461 |
| Net cash used in operating activities | -117,360 | -76,418 | -131,957 | -115,430 |
| Net cash acquired in the acquisition of a business | - | - | - | -277,104 |
| Purchases of property and equipment | 243 | 3,150 | 1,832 | 1,298 |
| Purchase of an intangible asset | 0 | 2,158 | - | 350 |
| Decrease in cash related to disposal of a business | 0 | 0 | -4,438 | - |
| Sales and maturities of investments | - | - | - | 0 |
| Purchases of investments | 2,306 | 500 | 1,000 | - |
| Net cash used in investing activities | -2,549 | -5,808 | -7,270 | 275,456 |
| Proceeds from issuance of common shares, net of issuance costs | 254,460 | 100,000 | 41,024 | 11,030 |
| Proceeds from equity incentive plans | -993 | 2,743 | 1,550 | 1,710 |
| Repayment of long-term debt and finance lease liabilities | 2,127 | 2,084 | 2,047 | 2,101 |
| Purchase of an intangible asset | 0 | 3,000 | - | - |
| Net cash provided by financing activities | 251,340 | 97,659 | 40,527 | 10,639 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,869 | 9,255 | 4,833 | -3,472 |
| Net change in cash, cash equivalents and restricted cash | 133,300 | 24,688 | -93,867 | 167,193 |
| Cash and cash equivalents at beginning of period | 533,845 | 509,157 | 603,024 | 435,831 |
| Cash and cash equivalents at end of period | 667,145 | 533,845 | 509,157 | 603,024 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)